Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 1.00 |
| ▸ | BCL2 | P10415 | 14/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.77 |
| ▸ | MDM4 | O15151 | 1/20 | 0.77 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | BID | P55957 | 1/20 | 0.77 |
| ▸ | BAX | Q07812 | 1/20 | 0.77 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.77 |
| ▸ | ASPH | Q12797 | 1/20 | 0.77 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.77 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.77 |
| ▸ | BAD | Q92934 | 1/20 | 0.77 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.77 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553692 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2MDM4BCL2L11 | |
| SCHEMBL554672 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2MDM4BCL2L11 | |
| SCHEMBL553690 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2MDM4BCL2L11 | |
| SCHEMBL554070 | 0.91 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL554782 | 0.91 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL554071 | 0.91 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL554648 | 0.91 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL3962942 | 0.91 | BCL2L1 (0.83) | BCL2L1BCL2BCL2L2MDM4BCL2L11 | |
| SCHEMBL1540286 | 0.90 | BCL2L1 (0.84) | BCL2L1BCL2BCL2L2MDM4BCL2L11 | |
| SCHEMBL554482 | 0.90 | BCL2L1 (0.81) | BCL2L1BCL2BCL2L2MDM4BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885BCL2L2 5/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885BCL2L2 5/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885BCL2L2 5/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | BCL2L1 6/4885BCL2 1/4885BCL2L2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.